Original Article
Abstract
References
Information
Suenaga R, Suka M, Hirao T, Hidaka I, Sakaida I, Ishida H. Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages. PLoS One 2021;16:e0248748.
10.1371/journal.pone.024874833793594PMC8016275
O'Horo J, Challener DW, Anderson RJ, Arndt RF, Ausman SE, Hall ST, et al. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. Mayo Clin Proc 2022;97:943-50.
10.1016/j.mayocp.2022.02.00935512884PMC8864104
Rosas J, Liaño FP, Cantó ML, Barea JMC, Beser AR, Rabasa JTA, et al. Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. Reumatol Clin (Engl Ed) 2022;18:150-6.
10.1016/j.reuma.2020.10.009PMC7699160
Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020;295:6785-97.
10.1074/jbc.RA120.01367932284326PMC7242698
- Publisher :The Korean Society for Microbiology
- Publisher(Ko) :대한미생물학회
- Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
- Volume : 52
- No :4
- Pages :149-159
- Received Date : 2022-09-06
- Revised Date : 2022-10-31
- Accepted Date : 2022-11-01
- DOI :https://doi.org/10.4167/jbv.2022.52.4.149